SIM 0500
Alternative Names: SIM-0500Latest Information Update: 19 Jun 2024
At a glance
- Originator Simcere Pharmaceutical Group
- Class Antineoplastics; Immunotherapies; Trispecific antibodies
- Mechanism of Action T lymphocyte stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Phase I Multiple myeloma
Most Recent Events
- 24 May 2024 Phase-I clinical trials in Multiple myeloma in China (Parenteral) (NCT06375044)
- 24 Apr 2024 Simcere Pharmaceutical Group plans a phase I trial for Multiple myeloma (Second-line therapy or greater) in China in May 2024 (NCT06375044)
- 22 Apr 2024 SIM 0500 receives Fast Track designation for Multiple myeloma [Parenteral] in USA